Epsilon M&A Deal Report - LGC Drug Development Solutions (DDS)

Transaction Multiples for the Valuation of Private Companies

Alliance Pharma > LGC Drug Development Solutions (DDS)

Announced Date : 16 May 2022

Type : Acquisition of Majority Stake

Deal Value : Yes

Acquirer : Alliance Pharma

Target: LGC Drug Development Solutions (DDS)

Target Country: United Kingdom

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> DDS is a contract research organization (CRO) that provides Bioanalytical solutions ( ...

No EMAT : 111924

Transaction multiples available

	EV/Sales	EV/Gross Profit	EV/EBITDA	EV/EBIT	Eq/PBT	P/E	Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating *

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1226

Example of comparable transactions on EMAT (same sub-sector):

Date	Acquirer	Target	Country	Multiples	See details
24/01/2023	Private Group led by Apax Partners	Porsolt	France	***
22/01/2022	EuroEyes International Eye Clinic	London Vision Clinic Partners	United Kingdom	**

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Subscribe to EMAT database